Your account is not claimed yet. You can sign up with ORCID to claim your account.

Thomas A Kirkland (Wytske M van Weerden, Wytske M Van Weerden)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 20

Top Venues

The Prostate

Cancers

International journal of molecular sciences

Cells

This page only lists publications with an associated author ORCID identifier.

Publications

Mitchell G Lawrence, Renea A Taylor, Georgia B Cuffe, Lisa S Ang, Ashlee K Clark, David L Goode, Laura H Porter, Clémentine Le Magnen, Nora M Navone, Jack A Schalken, Yuzhuo Wang, Thomas A Kirkland, Eva Corey, John T Isaacs, Peter S Nelson, Gail P Risbridger
The future of patient-derived xenografts in prostate cancer research. Nature reviews. Urology (2023)
Stefan A J Buck, Annelies Van Hemelryk, Corrina de Ridder, Debra Stuurman, Sigrun Erkens-Schulze, Sem Van 't Geloof, Wilma J Teubel, Stijn L W Koolen, Elena S Martens-Uzunova, Martin E van Royen, Ronald de Wit, Ron H J Mathijssen, Thomas A Kirkland
Darolutamide added to docetaxel augments antitumor effect in models of prostate cancer through cell cycle arrest at the G1-S transition. Molecular cancer therapeutics (2023)
Annelies Van Hemelryk, Sigrun Erkens-Schulze, Lifani Lim, Corrina M A de Ridder, Debra C Stuurman, Guido W Jenster, Martin E van Royen, Thomas A Kirkland
Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids. Cells 12 (10) (2023)
Hildert Bronkhorst, Thomas A Kirkland, Eline M Bunnik, H A E Hub Zwart
Awe and anxiety for cancer cells: connecting scientists and patients in a holistic approach of metastasis research. Research involvement and engagement 9 (1) (2023)
Annelies Van Hemelryk, Ingrid Tomljanovic, Corrina M A de Ridder, Debra C Stuurman, Wilma J Teubel, Sigrun Erkens-Schulze, Esther I Verhoef, Sebastiaan Remmers, Amrish J Mahes, G J L H Geert van Leenders, Martin E van Royen, Harmen J G van de Werken, Magda Grudniewska, Guido W Jenster, Thomas A Kirkland
Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling. Cells 11 (22) (2022)
Eline A M Ruigrok, Nicole S Verkaik, Erik de Blois, Corrina de Ridder, Debra Stuurman, Stefan J Roobol, Dik C van Gent, Marion de Jong, Thomas A Kirkland, Julie Nonnekens
Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment. International journal of molecular sciences 23 (14) (2022)
J Matthijs Moll, Johannes Hofland, Wilma J Teubel, Corina M A de Ridder, Angela E Taylor, Ralph Graeser, Wiebke Arlt, Guido W Jenster, Thomas A Kirkland
Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling. The Prostate 82 (5) (2022)
Gido Snaterse, Rosinda Mies, Thomas A Kirkland, Pim J French, Johan W Jonker, Adriaan B Houtsmuller, Martin E van Royen, Jenny A Visser, Johannes Hofland
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. Prostate cancer and prostatic diseases (2022)
Rosalba Mansi, Berthold A Nock, Simone U Dalm, Martijn B Busstra, Thomas A Kirkland, Theodosia Maina
Radiolabeled Bombesin Analogs. Cancers 13 (22) (2021)
Sanjiban Chakrabarty, William F Quiros-Solano, Maayke Mp Kuijten, Ben Haspels, Sandeep Mallya, Calvin Shun Yu Lo, Amr Othman, Cinzia Silvestri, Anja van de Stolpe, Nikolas Gaio, Hanny Odijk, Marieke van de Ven, Corrina M A de Ridder, Thomas A Kirkland, Jos Jonkers, Ronald Dekker, Nitika Taneja, Roland Kanaar, Dik C van Gent
A microfluidic cancer-on-chip platform predicts drug response using organotypic tumor slice culture. Cancer research (2021)
Annelies Van Hemelryk, Lisanne Mout, Sigrun Erkens-Schulze, Pim J French, Thomas A Kirkland, Martin E van Royen
Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing. Biomolecules 11 (11) (2021)
Arjanneke F van de Merbel, Geertje van der Horst, Maaike H van der Mark, Selas T F Bots, Diana J M van den Wollenberg, Corrina M A de Ridder, Debra Stuurman, Tilly Aalders, Sigrun Erkens-Schulz, Nadine van Montfoort, Wouter R Karthaus, Niven Mehra, Minke Smits, Jack A Schalken, Thomas A Kirkland, Wytske M van Weerden, Gabri van der Pluijm
Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models. Cancer gene therapy (2021)
Thomas A Kirkland
Patient-Derived Xenograft Models in Cancer Research. Cancers 13 (4) (2021)
Lisanne Mout, Jan M Moll, Mingqing Chen, Eleonora S de Morrée, Corrina M A de Ridder, Alice Gibson, Debra Stuurman, Ashraf Aghai, Sigrun Erkens-Schulze, Ron H J Mathijssen, Alex Sparreboom, Ronald de Wit, Martijn Paul Lolkema, Thomas A Kirkland
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer. British journal of cancer 123 (12) (2020)
Natasa Gaspar, Giorgia Zambito, Iris J C Dautzenberg, Steve J Cramer, Rob C Hoeben, Thomas A Kirkland, Joel R Walker, Thomas A Kirkland, Clemens W G M Löwik, Wytske M van Weerden, Jeroen de Vrij, Laura Mezzanotte
NanoBiT System and Hydrofurimazine for Optimized Detection of Viral Infection in Mice-A Novel in Vivo Imaging Platform. International journal of molecular sciences 21 (16) (2020)
Stanislav Drápela, Prashant Khirsariya, Thomas A Kirkland, Radek Fedr, Tereza Suchánková, Diana Búzová, Jan Cerveny, Aleš Hampl, Martin Puhr, William R Watson, Zoran Culig, Lumír Krejčí, Kamil Paruch, Karel Souček
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. Molecular oncology 14 (10) (2020)
Wenhao Zhang, Chen-Yi Liao, Hajar Chtatou, Luca Incrocci, Dik C van Gent, Thomas A Kirkland, Julie Nonnekens
Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair. Cancers 11 (10) (2019)
Eline A M Ruigrok, Thomas A Kirkland, Julie Nonnekens, Marion de Jong
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research. Pharmaceutics 11 (11) (2019)
J Matthijs Moll, Jinpei Kumagai, Martin E van Royen, Wilma J Teubel, Robert J van Soest, Pim J French, Yukio Homma, Guido Jenster, Ronald de Wit, Thomas A Kirkland
A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. The Prostate 79 (9) (2019)
Petra W van Duijn, Rute B Marques, Angelique C J Ziel-van der Made, Hanneke J A A van Zoggel, Ashraf Aghai, Cor Berrevoets, Reno Debets, Guido Jenster, Jan Trapman, Thomas A Kirkland
Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model. The Prostate 78 (13) (2018)

Thomas A Kirkland.css-eqlu8i{font-size:small;padding-left:4px;} (Wytske M van Weerden, Wytske M Van Weerden)

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas A Kirkland (Wytske M van Weerden, Wytske M Van Weerden)